Evidence map›Paper›PMID 34063894›Full record

ArticleCancers2021

Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study.

Lina Benajiba, Jérôme Lambert, Roberta La Selva, Delphine Cochereau, Barouyr Baroudjian, Jennifer Roux, Jérôme Le Goff, Cécile Pages, Maxime Battistella, Julie Delyon and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Lina BenajibaUniversité de Paris, AP-HP, Clinical Investigations Center, INSERM U944, Saint Louis Hospital, 75010 Paris, France.ORCID 0000-0001-5440-1115
Jérôme LambertUniversité de Paris, AP-HP, Biostatistics Department, Saint Louis Hospital, 75010 Paris, France.
Roberta La SelvaA.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
Delphine CochereauUniversité de Paris, AP-HP, Dermatology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.
Barouyr BaroudjianUniversité de Paris, AP-HP, Dermatology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.
Jennifer RouxUniversité de Paris, AP-HP, Dermatology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.
Jérôme Le GoffUniversité de Paris, AP-HP, Microbiology Department, Saint Louis Hospital, 75010 Paris, France.
Cécile PagesUniversité de Paris, AP-HP, Dermatology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.
Maxime BattistellaUniversité de Paris, AP-HP, Pathology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.
Julie DelyonUniversité de Paris, AP-HP, Dermatology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.ORCID 0000-0002-4557-3377
Céleste LebbéUniversité de Paris, AP-HP, Dermatology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.
Inserm · FRUniversité Paris Cité · FRAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough several studies described the clinical course of epidemic and post-transplant Kaposi's Sarcoma (KS), the lack of large cohorts of classic/endemic KS, precluded such characterization.

methodsWe used multi-state modelling in a retrospective monocentric study to evaluate global disease evolution and identify risk factors for systemic treatment (ST) initiation. 160 classic/endemic KS patients consecutively diagnosed between 1990 and 2013 were included.

results41.2% of classic/endemic KS patients required ST. Cumulative incidence of ST after 2 years of follow-up was 28.4% [95% CI: 20.5; 35.5]. Multivariate analysis identified six risk factors for ST initiation: time between first symptoms and diagnosis ≥1 year, endemic KS, total number of lesions ≥10, visceral, head or neck localization and presence of edema. Type of ST, type of KS, age and time between diagnosis and ST were not associated with response. Mean treatment-free time during the first 5 years following ST was 44 months for interferon and 44.6 months for chemotherapy treated patients (Mean difference: -0.5 months [95% CI: -9.5; 4.9]).

conclusionsOur study reveals ST risk factors in classic/endemic KS and highlights the clinical aggressiveness of the endemic KS subtype. No efficacy difference was observed between standard of care treatments, enabling treatment choice based on patient's fitness.

Indexed as

chemotherapyclassical and endemic Kaposi Sarcomainterferonmulti-state modellingsystemic treatmenttreatment free interval

Identifiers

PMID34063894
PMCPMC8196666
OpenAlexW3160538793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.